Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: A meta-analysis of 19 studies

American Journal of Nephrology

Volumn 40, Issue 3, 2014, Pages 263-279

  Covic, Adrian ^a   Nistor, Ionut ^a   Donciu, Mihaela Dora ^a   Dumea, Raluca ^a   Bolignano, Davide ^b   Goldsmith, David ^c  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b CNR   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anemia; Chronic kidney disease; CKD progression; Erythropoiesis stimulating agents; ESA; Meta analysis; Systematic review

Indexed keywords

ANTIANEMIC AGENT; CREATININE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ALBUMINURIA; ANEMIA; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROTEINURIA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT REFUSAL; BLOOD; BLOOD PRESSURE; CHEMISTRY; COMPLICATION; DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANEMIA; BLOOD PRESSURE; CREATININE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; GLOMERULAR FILTRATION RATE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84908301722     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000366025     Document Type: Review

References (43)

1. Collins AJ, et al: 'United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 2012; 59(1 suppl 1):A7, e1-e420.
2. Go AS, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Kerr M, et al: Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012; 27(suppl 3): iii73-iii80.
4. Fried LF, et al: Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16: 3728-3735.
5. Iff S, et al: Reduced estimated GFR and cancer mortality. Am J Kidney Dis 2014; 63: 23-30.
6. Casas JP, et al: Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
7. Strippoli GF, et al: Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; 4 : Cd006257.
8. Gansevoort RT, et al: Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352.
9. Jha V, et al: Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272.
10. Gouva C, et al: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
11. Drueke TB, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
12. Palmer SC, et al: Meta-analysis: erythropoiesis- stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
13. Tsubakihara Y, et al: High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial 2012; 16: 529-540.
14. Villar E, et al: Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. J Diabetes Complications 2011; 25: 237-243.
15. Choukroun G, et al: Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012; 23: 360-368.
16. Centers for Disease Control and Prevention: National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, GA: U.S. Department of Health and Human Services, CDC, 2010, National Chronic Kidney Disease Fact Sheet 2010.
17. Dalrymple LS, et al: Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011; 26: 379-385.
18. Tonelli M, et al: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
19. Higgins JPT, Greeen S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.cochranehandbook. org.
20. Higgins JP, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
21. Thompson SG, Sharp SJ: Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-2708.
22. Kleinman KS, et al: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989; 14: 486-495.
23. Watson AJ, et al: Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89: 432-435.
24. Clyne N, Jogestrand T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992; 60: 390-396.
25. Revicki DA, et al: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554.
26. Kuriyama S, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
27. Furuland H, et al: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361.
28. Roger SD: Effects of early and late intervention with epoetin on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156.
29. Levin A, et al: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811.
30. Rossert J, et al: Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-750.
31. Singh AK, et al: Correction of anemia with epoetin alfa in chronic kidney disease [see comment]. N Engl J Med 2006; 355: 2085-2098.
32. Macdougall IC, Temple RM, Kwan JT: Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, openlabel, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007; 22: 784-793.
33. Ritz E, et al: Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207.
34. Cianciaruso B, et al: Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. J Nephrol 2008; 21: 861-870.
35. Pfeffer MA, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
36. KDOQI, KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
37. Akizawa T, et al: Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial 2011; 15: 431-440.
38. De Nicola L, et al: Responsiveness to erythropoiesis- stimulating agents in chronic kidney disease: does geography matter? Drugs 2014; 74: 159-168.
39. Molnar MZ, et al: Prevalence and management of anaemia in renal transplant recipients: data from ten European centres. Nephron Clin Pract 2011; 117:c127-c134.
40. Strippoli GF, et al: Hemoglobin targets for the anemia of chronic kidney disease: a metaanalysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 3154-3165.
41. Cody June D, et al: Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005;3 . DOI: 10.1002/14651858. CD003266.
42. Drueke TB, Parfrey PS: Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012; 82: 952-960.
43. Locatelli F, et al: Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359.